{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:13:05Z","timestamp":1793056385667,"version":"4.5.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,2]],"date-time":"2020-08-02T00:00:00Z","timestamp":1596326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,2]],"date-time":"2020-08-02T00:00:00Z","timestamp":1596326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s00296-020-04665-7","type":"journal-article","created":{"date-parts":[[2020,8,2]],"date-time":"2020-08-02T08:02:43Z","timestamp":1596355363000},"page":"33-42","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Immune checkpoint inhibitor-induced musculoskeletal manifestations"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2446-5916","authenticated-orcid":false,"given":"Foteini","family":"Angelopoulou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9697-7902","authenticated-orcid":false,"given":"Dimitrios","family":"Bogdanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0364-1642","authenticated-orcid":false,"given":"Theodoros","family":"Dimitroulas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7670-3314","authenticated-orcid":false,"given":"Lazaros","family":"Sakkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8027-3655","authenticated-orcid":false,"given":"Dimitrios","family":"Daoussis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,2]]},"reference":[{"key":"4665_CR1","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252\u2013264","journal-title":"Nat Rev Cancer"},{"key":"4665_CR2","doi-asserted-by":"crossref","first-page":"8509","DOI":"10.1002\/jcp.27782","volume":"234","author":"B Farhood","year":"2019","unstructured":"Farhood B, Najafi M, Mortezaee K (2019) CD8 + cytotoxic T lymphocytes in cancer immunotherapy: a review. J Cell Physiol 234:8509\u20138521","journal-title":"J Cell Physiol"},{"key":"4665_CR3","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","volume":"3","author":"EA Tivol","year":"1995","unstructured":"Tivol EA, Borriello F, Nicola Schweitzer A, Lynch WP, Bluestone JA, Sharpe AH (1995) Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3:541\u2013547","journal-title":"Immunity"},{"issue":"2","key":"4665_CR4","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","volume":"11","author":"H Nishimura","year":"1999","unstructured":"Nishimura H, Nose M, Hiai H, Minato N, Honjo T (1999) Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11(2):141\u2013151","journal-title":"Immunity"},{"key":"4665_CR5","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/annonc\/mdx686","volume":"29","author":"A Rotte","year":"2018","unstructured":"Rotte A, Jin JY, Lemaire V (2018) Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy. Ann Oncol 29:71\u201383","journal-title":"Ann Oncol"},{"key":"4665_CR6","first-page":"109","volume":"50","author":"Y-J Park","year":"2018","unstructured":"Park Y-J, Kuen D-S, Chung Y (2018) Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance. Exp Mol Med 50:109","journal-title":"Exp Mol Med"},{"key":"4665_CR7","doi-asserted-by":"crossref","first-page":"317","DOI":"10.7555\/JBR.31.20160168","volume":"32","author":"ES Webb","year":"2018","unstructured":"Webb ES, Liu P, Baleeiro R, Lemoine NR, Yuan M, Wang Y-H (2018) Immune checkpoint inhibitors in cancer therapy. J Biomed Res 32:317\u2013326","journal-title":"J Biomed Res"},{"key":"4665_CR8","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378:158\u2013168","journal-title":"N Engl J Med"},{"key":"4665_CR9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","volume":"44","author":"L Spain","year":"2016","unstructured":"Spain L, Diem S, Larkin J (2016) Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 44:51\u201360","journal-title":"Cancer Treat Rev"},{"key":"4665_CR10","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1093\/rheumatology\/kez361","volume":"59","author":"D Daoussis","year":"2020","unstructured":"Daoussis D, Kraniotis P, Filippopoulou A, Argiriadi R, Theodoraki S, Makatsoris T, Koutras A, Kehagias I, Papachristou DJ, Solomou A, Haralabos Kalofonos S-NL (2020) MRI study of immune checkpoint inhibitor\u2013induced musculoskeletal manifestations. Myofasciitis is the prominent imaging finding. Rheumatology (Oxford) 59:1041\u20131050","journal-title":"Rheumatology (Oxford)"},{"key":"4665_CR11","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1136\/annrheumdis-2017-212257","volume":"77","author":"M Kostine","year":"2018","unstructured":"Kostine M, Rouxel L, Barnetche T, Veillon R, Martin F, Dutriaux C et al (2018) Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study. Ann Rheum Dis 77:393\u2013398","journal-title":"Ann Rheum Dis"},{"key":"4665_CR12","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.autrev.2018.05.002","volume":"17","author":"J Narv\u00e1ez","year":"2018","unstructured":"Narv\u00e1ez J, Nolla JM, Garc\u00eda X, del Muro J, Lluch JAN, Domingo-Domenech E et al (2018) Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: fasciitis with myositis syndrome as a new complication of immunotherapy. Autoimmun Rev 17:1040\u20131045","journal-title":"Autoimmun Rev"},{"key":"4665_CR13","doi-asserted-by":"crossref","first-page":"vii68","DOI":"10.1093\/rheumatology\/kez295","volume":"58","author":"M Kostine","year":"2019","unstructured":"Kostine M, Truchetet M-E, Schaeverbeke T (2019) Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy. Rheumatology 58:vii68\u2013vii74","journal-title":"Rheumatology"},{"key":"4665_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217139","author":"M Kostine","year":"2020","unstructured":"Kostine M, Finckh A, Bingham CO, Visser K, Leipe J, Schulze-Koops H et al (2020) EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217139","journal-title":"Ann Rheum Dis"},{"key":"4665_CR15","doi-asserted-by":"crossref","first-page":"239","DOI":"10.31138\/mjr.31.2.239","volume":"31","author":"D Daoussis","year":"2020","unstructured":"Daoussis D, Melissaropoulos K, Dimitroulas T, Andreadis H, Christopoulou A, Douganiotis G et al (2020) Immune checkpoint inhibitor-induced musculoskeletal manifestations. A multicentre prospective study. Mediterr J Rheumatol 31:239","journal-title":"Mediterr J Rheumatol"},{"key":"4665_CR16","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/art.40745","volume":"71","author":"MD Richter","year":"2019","unstructured":"Richter MD, Crowson C, Kottschade LA, Finnes HD, Markovic SN, Thanarajasingam U (2019) Rheumatic syndromes associated with immune checkpoint inhibitors: a single-center cohort of sixty-one patients. Arthritis Rheumatol 71:468\u2013475","journal-title":"Arthritis Rheumatol"},{"key":"4665_CR17","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejca.2017.05.032","volume":"82","author":"S Le Burel","year":"2017","unstructured":"Le Burel S, Champiat S, Mateus C, Marabelle A, Michot JM, Robert C et al (2017) Prevalence of immune-related systemic adverse events in patients treated with anti-programmed cell death 1\/anti-programmed cell death-ligand 1 agents: a single-centre pharmacovigilance database analysis. Eur J Cancer 82:34\u201344","journal-title":"Eur J Cancer"},{"key":"4665_CR18","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.autrev.2018.01.003","volume":"17","author":"M Lidar","year":"2018","unstructured":"Lidar M, Giat E, Garelick D, Horowitz Y, Amital H, Steinberg-Silman Y et al (2018) Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors. Autoimmun Rev 17:284\u2013289","journal-title":"Autoimmun Rev"},{"key":"4665_CR19","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/annrheumdis-2016-209595","volume":"76","author":"LC Cappelli","year":"2017","unstructured":"Cappelli LC, Gutierrez AK, Baer AN, Albayda J, Manno RL, Haque U et al (2017) Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis 76:43\u201350","journal-title":"Ann Rheum Dis"},{"key":"4665_CR20","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2017-211216","volume":"76","author":"R Belkhir","year":"2017","unstructured":"Belkhir R, Le Burel S, Dunogeant L, Marabelle A, Hollebecque A, Besse B et al (2017) Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment. Ann Rheum Dis 76:1747\u20131750","journal-title":"Ann Rheum Dis"},{"key":"4665_CR21","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.semarthrit.2018.10.012","volume":"48","author":"MJ Mooradian","year":"2019","unstructured":"Mooradian MJ, Nasrallah M, Gainor JF, Reynolds KL, Cohen JV, Lawrence DP et al (2019) Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: a single center experience. Semin Arthritis Rheum 48:1127\u20131132","journal-title":"Semin Arthritis Rheum"},{"key":"4665_CR22","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/acr.23467","volume":"71","author":"MH Smith","year":"2019","unstructured":"Smith MH, Bass AR (2019) Arthritis after cancer immunotherapy: symptom duration and treatment response. Arthritis Care Res 71:362\u2013366","journal-title":"Arthritis Care Res"},{"key":"4665_CR23","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.semarthrit.2018.05.006","volume":"48","author":"M Shah","year":"2019","unstructured":"Shah M, Tayar JH, Abdel-Wahab N, Suarez-Almazor ME (2019) Myositis as an adverse event of immune checkpoint blockade for cancer therapy. Semin Arthritis Rheum 48:736\u2013740","journal-title":"Semin Arthritis Rheum"},{"key":"4665_CR24","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1177\/1078155218822707","volume":"25","author":"J Lee","year":"2019","unstructured":"Lee J, Graham A, Sion A (2019) Evaluation of arthralgias in adult oncology patients receiving immune checkpoint inhibitors. J Oncol Pharm Pract 25:1867\u20131872","journal-title":"J Oncol Pharm Pract"},{"key":"4665_CR25","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.semarthrit.2018.02.011","volume":"48","author":"LC Cappelli","year":"2018","unstructured":"Cappelli LC, Brahmer JR, Forde PM, Le DT, Lipson EJ, Naidoo J et al (2018) Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen. Semin Arthritis Rheum 48:553\u2013557","journal-title":"Semin Arthritis Rheum"},{"key":"4665_CR26","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00262-017-2069-9","volume":"67","author":"K Buder-Bakhaya","year":"2018","unstructured":"Buder-Bakhaya K, Benesova K, Schulz C, Anwar H, Dimitrakopoulou-Strauss A, Weber TF et al (2018) Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies. Cancer Immunol Immunother 67:175\u2013182","journal-title":"Cancer Immunol Immunother"},{"key":"4665_CR27","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejca.2018.09.027","volume":"105","author":"EL Mitchell","year":"2018","unstructured":"Mitchell EL, Lau PKH, Khoo C, Liew D, Leung J, Liu B et al (2018) Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: a case series. Eur J Cancer 105:88\u2013102","journal-title":"Eur J Cancer"},{"key":"4665_CR28","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","volume":"60","author":"L Zimmer","year":"2016","unstructured":"Zimmer L, Goldinger SM, Hofmann L, Loquai C, Ugurel S, Thomas I et al (2016) Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer 60:210\u2013225","journal-title":"Eur J Cancer"},{"key":"4665_CR29","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2018.09.033","volume":"106","author":"A Moreira","year":"2019","unstructured":"Moreira A, Loquai C, Pf\u00f6hler C, K\u00e4hler KC, Knauss S, Heppt MV et al (2019) Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors. Eur J Cancer 106:12\u201323","journal-title":"Eur J Cancer"},{"key":"4665_CR30","doi-asserted-by":"crossref","first-page":"e000412","DOI":"10.1136\/rmdopen-2016-000412","volume":"3","author":"C Calabrese","year":"2017","unstructured":"Calabrese C, Kirchner E, Kontzias K, Velcheti V, Calabrese LH (2017) Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity. RMD Open 3:e000412","journal-title":"RMD Open"},{"issue":"2","key":"4665_CR31","doi-asserted-by":"publisher","first-page":"e000714","DOI":"10.1136\/rmdopen-2018-000714","volume":"4","author":"J Leipe","year":"2018","unstructured":"Leipe J, Christ LA, Arnoldi AP, Mille E, Berger F, Heppt M et al (2018) Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy. RMD Open 4(2):e000714. https:\/\/doi.org\/10.1136\/rmdopen-2018-000714","journal-title":"RMD Open"},{"key":"4665_CR32","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/1756-185X.13444","volume":"22","author":"DFL Liew","year":"2019","unstructured":"Liew DFL, Leung JLY, Liu B, Cebon J, Frauman AG, Buchanan RRC (2019) Association of good oncological response to therapy with the development of rheumatic immune-related adverse events following PD-1 inhibitor therapy. Int J Rheum Dis 22:297\u2013302","journal-title":"Int J Rheum Dis"},{"key":"4665_CR33","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.semarthrit.2017.10.018","volume":"47","author":"WF Kuswanto","year":"2018","unstructured":"Kuswanto WF, MacFarlane LA, Gedmintas L, Mulloy A, Choueiri TK, Bermas BL (2018) Rheumatologic symptoms in oncologic patients on PD-1 inhibitors. Semin Arthritis Rheum 47:907\u2013910","journal-title":"Semin Arthritis Rheum"},{"key":"4665_CR34","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/art.38282","volume":"66","author":"BL Goldstein","year":"2014","unstructured":"Goldstein BL, Gedmintas L, Todd DJ (2014) Concise communication. Arthritis Rheumatol 66:768\u2013769","journal-title":"Arthritis Rheumatol"},{"key":"4665_CR35","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/CJI.0000000000000060","volume":"38","author":"MMK Chan","year":"2015","unstructured":"Chan MMK, Kefford RF, Carlino M, Clements A, Manoliosz N (2015) Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma case presentation case 1. J Immunother 38:37\u201339","journal-title":"J Immunother"},{"key":"4665_CR36","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jbspin.2016.01.007","volume":"84","author":"B Garel","year":"2017","unstructured":"Garel B, Kramkimel N, Trouvin AP, Frantz C, Dupin N (2017) Pembrolizumab-induced polymyalgia rheumatica in two patients with metastatic melanoma. Jt Bone Spine 84:233\u2013234","journal-title":"Jt Bone Spine"},{"key":"4665_CR37","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1200\/JCO.2017.35.15_suppl.3018","volume":"35","author":"C Weinstock","year":"2017","unstructured":"Weinstock C, Singh H, Maher VE, Kim G, Pazdur R (2017) FDA analysis of patients with baseline autoimmune diseases treated with PD-1\/PD-L1 immunotherapy agents. J Clin Oncol 35:3018\u20133018","journal-title":"J Clin Oncol"},{"key":"4665_CR38","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1002\/art.41068","volume":"71","author":"A Tison","year":"2019","unstructured":"Tison A, Qu\u00e9r\u00e9 G, Misery L, Funck-Brentano E, Danlos FX, Routier E et al (2019) Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide Multicenter Cohort Study. Arthritis Rheumatol 71:2100\u20132111","journal-title":"Arthritis Rheumatol"},{"key":"4665_CR39","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00262-019-02321-z","volume":"68","author":"KL Kehl","year":"2019","unstructured":"Kehl KL, Yang S, Awad MM, Palmer N, Kohane IS, Schrag D (2019) Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer. Cancer Immunol Immunother 68:917\u2013926","journal-title":"Cancer Immunol Immunother"},{"key":"4665_CR40","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","volume":"2","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F et al (2016) Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol 2:234\u2013240","journal-title":"JAMA Oncol"},{"key":"4665_CR41","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ejca.2016.12.038","volume":"75","author":"R Gutzmer","year":"2017","unstructured":"Gutzmer R, Koop A, Meier F, Hassel JC, Terheyden P, Zimmer L et al (2017) Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. Eur J Cancer 75:24\u201332","journal-title":"Eur J Cancer"},{"key":"4665_CR42","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2017.12.008","volume":"91","author":"FX Danlos","year":"2018","unstructured":"Danlos FX, Voisin AL, Dyevre V, Michot JM, Routier E, Taillade L et al (2018) Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. Eur J Cancer 91:21\u201329","journal-title":"Eur J Cancer"},{"key":"4665_CR43","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","volume":"28","author":"AM Menzies","year":"2017","unstructured":"Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ et al (2017) Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol 28:368\u2013376","journal-title":"Ann Oncol"},{"key":"4665_CR44","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2017.77.0305","volume":"36","author":"GC Leonardi","year":"2018","unstructured":"Leonardi GC, Gainor JF, Altan M, Kravets S, Dahlberg SE, Gedmintas L et al (2018) Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders. J Clin Oncol 36:1905\u20131912","journal-title":"J Clin Oncol"},{"key":"4665_CR45","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1093\/annonc\/mdw056","volume":"27","author":"B Lee","year":"2016","unstructured":"Lee B, Wong A, Kee D, Neeson P, Shackleton M, McArthur G et al (2016) The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma. Ann Oncol 27:1174\u20131177","journal-title":"Ann Oncol"},{"key":"4665_CR46","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.lungcan.2017.04.007","volume":"108","author":"J Ruiz-Ba\u00f1obre","year":"2017","unstructured":"Ruiz-Ba\u00f1obre J, P\u00e9rez-Pamp\u00edn E, Garc\u00eda-Gonz\u00e1lez J, G\u00f3mez-Caama\u00f1o A, Bar\u00f3n-Duarte FJ, L\u00f3pez-L\u00f3pez R et al (2017) Development of psoriatic arthritis during nivolumab therapy for metastatic non-small cell lung cancer, clinical outcome analysis and review of the literature. Lung Cancer 108:217\u2013221","journal-title":"Lung Cancer"},{"issue":"2","key":"4665_CR47","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s40425-014-0035-z","volume":"14","author":"C Kyi","year":"2014","unstructured":"Kyi C, Carvajal RD, Wolchok JD, Postow MA (2014) Ipilimumab in patients with melanoma and autoimmune disease. J Immunother Cancer 14(2):35","journal-title":"J Immunother Cancer"},{"key":"4665_CR48","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1007\/s10067-019-04451-2","volume":"38","author":"J Roberts","year":"2019","unstructured":"Roberts J, Smylie M, Walker J, Basappa NS, Chu Q, Kolinsky M et al (2019) Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor-induced inflammatory arthritis. Clin Rheumatol 38:1513\u20131519","journal-title":"Clin Rheumatol"},{"key":"4665_CR49","doi-asserted-by":"crossref","first-page":"102595","DOI":"10.1016\/j.autrev.2020.102595","volume":"19","author":"J Roberts","year":"2020","unstructured":"Roberts J, Ennis D, Hudson M, Ye C, Saltman A, Rottapel R et al (2020) Rheumatic immune-related adverse events associated with cancer immunotherapy: a nationwide multi-center cohort. Autoimmun Rev 19:102595","journal-title":"Autoimmun Rev"},{"key":"4665_CR50","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05162-9","author":"Y Liu","year":"2020","unstructured":"Liu Y, Jaquith JM, Mccarthy-Fruin K, Zhu X, Zhou X, Li Y et al (2020) Immune checkpoint inhibitor-induced inflammatory arthritis: a novel clinical entity with striking similarities to seronegative rheumatoid arthritis. Clin Rheumatol. https:\/\/doi.org\/10.1007\/s10067-020-05162-9","journal-title":"Clin Rheumatol"},{"key":"4665_CR51","doi-asserted-by":"crossref","first-page":"102586","DOI":"10.1016\/j.autrev.2020.102586","volume":"19","author":"Y Allenbach","year":"2020","unstructured":"Allenbach Y, Anquetil C, Manouchehri A, Benveniste O, Lambotte O, Lebrun-Vignes B et al (2020) Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities. Autoimmun Rev 19:102586","journal-title":"Autoimmun Rev"},{"key":"4665_CR52","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217018","author":"T Nguyen","year":"2020","unstructured":"Nguyen T, Maria ATJ, Ladhari C, Palassin P, Quantin X, Lesage C et al (2020) Rheumatic disorders associated with immune checkpoint inhibitors: What about myositis? An analysis of the WHO\u2019s adverse drug reactions database. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217018","journal-title":"Ann Rheum Dis"},{"key":"4665_CR53","doi-asserted-by":"crossref","first-page":"102455","DOI":"10.1016\/j.autrev.2019.102455","volume":"19","author":"A Matas-Garc\u00eda","year":"2020","unstructured":"Matas-Garc\u00eda A, Milisenda JC, Selva-O\u2019Callaghan A, Prieto-Gonz\u00e1lez S, Padrosa J, Cabrera C et al (2020) Emerging PD-1 and PD-1L inhibitors-associated myopathy with a characteristic histopathological pattern. Autoimmun Rev 19:102455","journal-title":"Autoimmun Rev"},{"key":"4665_CR54","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217225","author":"G Martin de Fremont","year":"2020","unstructured":"Martin de Fremont G, Belkhir R, Henry J, Voisin AL, Lambotte O, Besson FL et al (2020) Features of polymyalgia rheumatic-like syndrome after immune checkpoint inhibitor therapy. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217225","journal-title":"Ann Rheum Dis"},{"key":"4665_CR55","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217381","author":"KSM Van Der Geest","year":"2020","unstructured":"Van Der Geest KSM, Sandovici M, Rutgers A, Hiltermann TJN, Oosting SF, Slart RHJA et al (2020) Imaging in immune checkpoint inhibitor-induced polymyalgia rheumatica. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217381","journal-title":"Ann Rheum Dis"},{"key":"4665_CR56","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000281","author":"W Murray-Brown","year":"2020","unstructured":"Murray-Brown W, Wilsdon TD, Weedon H, Proudman S, Sukumaran S, Klebe S et al (2020) Nivolumab-induced synovitis is characterized by florid T cell infiltration and rapid resolution with synovial biopsy-guided therapy. J Immunother cancer. https:\/\/doi.org\/10.1136\/jitc-2019-000281","journal-title":"J Immunother cancer"},{"key":"4665_CR57","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217605","author":"CA Moura","year":"2020","unstructured":"Moura CA, Moura CG (2020) Severe polymyalgia-like symptoms secondary to anti-PD1 therapy successfully managed without discontinuing checkpoint inhibitor. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217605","journal-title":"Ann Rheum Dis"},{"key":"4665_CR58","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/annrheumdis-2019-216109","volume":"79","author":"TJ Braaten","year":"2019","unstructured":"Braaten TJ, Brahmer JR, Forde PM, Le D, Lipson EJ, Naidoo J et al (2019) Checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. Ann Rheum Dis 79:332\u2013338","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-020-04665-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-020-04665-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-020-04665-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T01:29:06Z","timestamp":1696469346000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-020-04665-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,2]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["4665"],"URL":"https:\/\/doi.org\/10.1007\/s00296-020-04665-7","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,2]]},"assertion":[{"value":"19 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}